1. Home
  2. OMER vs WRN Comparison

OMER vs WRN Comparison

Compare OMER & WRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Omeros Corporation

OMER

Omeros Corporation

HOLD

Current Price

$14.75

Market Cap

772.8M

Sector

Health Care

ML Signal

HOLD

Logo Western Copper and Gold Corporation

WRN

Western Copper and Gold Corporation

HOLD

Current Price

$2.80

Market Cap

620.5M

ML Signal

HOLD

Company Overview

Basic Information
Metric
OMER
WRN
Founded
1994
2006
Country
United States
Canada
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Metal Mining
Sector
Health Care
Basic Materials
Exchange
Nasdaq
Nasdaq
Market Cap
772.8M
620.5M
IPO Year
2008
2006

Fundamental Metrics

Financial Performance
Metric
OMER
WRN
Price
$14.75
$2.80
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
3
Target Price
$32.50
$4.58
AVG Volume (30 Days)
1.1M
2.0M
Earning Date
05-14-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
98.15
N/A
EPS
N/A
N/A
Revenue
$29,868,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$233.22
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.95
$1.02
52 Week High
$17.65
$4.26

Technical Indicators

Market Signals
Indicator
OMER
WRN
Relative Strength Index (RSI) 69.42 50.80
Support Level $10.82 $2.66
Resistance Level $17.65 $3.02
Average True Range (ATR) 0.69 0.13
MACD 0.18 0.01
Stochastic Oscillator 84.85 51.39

Price Performance

Historical Comparison
OMER
WRN

About OMER Omeros Corporation

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

About WRN Western Copper and Gold Corporation

Western Copper & Gold Corp is a Canada-based exploration-stage company. The company is engaged in the exploration and development of the Casino mineral property located in Yukon, Canada (the Casino Project). The Casino can deliver the critical minerals necessary for the energy transition while serving as an engine for long-term economic growth and prosperity in the North.

Share on Social Networks: